TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 51.02B
Enterprise Value 31.05B
Trailing P/E N/A
Forward P/E 1-4.95
PEG Ratio (5 yr expected) 1-0.04
Price/Sales (ttm)17.75
Price/Book (mrq)N/A
Enterprise Value/Revenue 318.33
Enterprise Value/EBITDA 6-4.30

Trading Information

Stock Price History

Beta (3Y Monthly) 1.49
52-Week Change 3-31.14%
S&P500 52-Week Change 36.04%
52 Week High 335.48
52 Week Low 315.18
50-Day Moving Average 316.71
200-Day Moving Average 322.19

Share Statistics

Avg Vol (3 month) 3285.62k
Avg Vol (10 day) 3196.65k
Shares Outstanding 556.11M
Float 33.47M
% Held by Insiders 15.69%
% Held by Institutions 186.30%
Shares Short (Jun 28, 2019) 45.86M
Short Ratio (Jun 28, 2019) 417.42
Short % of Float (Jun 28, 2019) 442.31%
Short % of Shares Outstanding (Jun 28, 2019) 410.44%
Shares Short (prior month May 31, 2019) 45.88M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-431.17%

Management Effectiveness

Return on Assets (ttm)-30.58%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)57.39M
Revenue Per Share (ttm)1.05
Quarterly Revenue Growth (yoy)-35.80%
Gross Profit (ttm)-141.69M
EBITDA -244.49M
Net Income Avi to Common (ttm)-223.02M
Diluted EPS (ttm)-4.10
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)445.76M
Total Cash Per Share (mrq)7.94
Total Debt (mrq)511.7M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)4.11
Book Value Per Share (mrq)-2.02

Cash Flow Statement

Operating Cash Flow (ttm)-243.88M
Levered Free Cash Flow (ttm)-118.54M